NCT06476249 Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection
| NCT ID | NCT06476249 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hematology department of the 920th hospital |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-03-01 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer, as the main cause of cancer-related deaths in both males and females, is a great risk to human health. Pulmonary resection is the most applicable to early-stage lung cancer diagnoses and considered the best curative options. Coughing is a prominent symptom among postoperative complications, with approximately 18%-50% of patients experiencing persistent coughing after surgery. This study is a prospective observational study and is expected to be carried out in a large tertiary hospital. This cohort is expected to include 1000 participants for three years. Patients with pulmonary nodules on chest CT will be divided into two groups based on the presence or absence of cough symptoms on admission. The investigators decided whether to include patients in this cohort study strictly based on the inclusion and exclusion criteria. The severity of cough, the trajectory of cough change, and the physiological and social burden caused by cough will be reflected by the results of LCQ-MC, CSS, HARQ, and VAS. LCQ-MC, CSS, HARQ, and VAS are just a few of the questionnaires that are widely used to investigate the cough and severity of the respondent. The included variables included age, gender, Height, Weight, education level, smoking history, alcohol history, preoperative lung function, nodule size, preoperative and postoperative blood routine (such as white blood cell count, neutrophil count, etc.), blood biochemistry (such as C-reactive protein, PCT, etc.), liver and kidney function test results, surgical method, surgical site, operation duration, anesthesia method, anesthesia duration, lymph node dissection, pathological results, chest tube caliber, number of days of catheterization, use of cough drugs, use of non-steroidal anti-inflammatory drugs, Number of days in hospital and number of outpatient visits due to cough.
Eligibility Criteria
Inclusion Criteria: ● Patients aged 18 years or older and less than or equal to 70 years of age who underwent surgery with video-assisted thoracoscopic pneumonectomy. Exclusion Criteria: * Pre-existing cough before surgery (e.g. asthma, taking ACEI Drugs, etc.) * Distant metastasis of tumor * Combined pregnancy or breastfeeding * Combined with other systemic major diseases (such as malignant swelling, chronic liver insufficiency, chronic renal insufficiency, etc.) * Suffering from mental illness * Refusal of follow-up or incomplete clinical information * Poor compliance and other groups considered by the investigator not suitable for inclusion
Contact & Investigator
Wenk Cai, doctor
STUDY CHAIR
the Vice-President of the 920th Hospital of the Joint Logistics Support Force
Frequently Asked Questions
Who can join the NCT06476249 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06476249 currently recruiting?
Yes, NCT06476249 is actively recruiting participants. Contact the research team at zhangrong00626@126.com for enrollment information.
Where is the NCT06476249 trial being conducted?
This trial is being conducted at Kunming, China.
Who is sponsoring the NCT06476249 clinical trial?
NCT06476249 is sponsored by Hematology department of the 920th hospital. The principal investigator is Wenk Cai, doctor at the Vice-President of the 920th Hospital of the Joint Logistics Support Force. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.